Phaxiam Therapeutics and Vetophage announced the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins in the fight against antimicrobial resistance. Vetophage is a Lyon-based biotechnology company founded in 2017. It develops new tools to detect pathogenic bacteria and alternative solutions to antibiotics based on phages and endolysins to tackle antimicrobial resistance in animals. Vetophage benefits from a wide range of capabilities for the discovery, identification and characterization of phages and endolysins. The company enables Phaxiam Therapeutics to screen its broad phage and endolysin bank targeting highly antimicrobial-resistant infections. This agreement gives Phaxiam Therapeutics exclusive licensing options on specified phages and endolysins in human health from the Vetophage platform, to further strengthen its product portfolio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
